Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Filovirus alphavaccine
- Development stage
- Preclinical
- Lead developer
- AlphaVax
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The filovirus alphavaccine is a recombinant vaccine candidate developed by AlphaVax for biodefense against filovirus infections, including Ebola and Marburg viruses. It utilizes the company's proprietary Viral Replicon Particle (VRP) technology, which is based on a replication-defective alphavirus vector derived from the Venezuelan Equine Encephalitis (VEE) virus. The VRPs carry RNA encoding specific filovirus antigens; once injected, they infect host cells and express these antigens to stimulate robust humoral (antibody) and cellular (T-cell) immune responses. Because the vector is replication-defective, it cannot produce new infectious viral particles, enhancing the safety profile while maintaining the high immunogenicity characteristic of alphavirus infections. This platform is particularly suited for biodefense due to its ability to induce rapid protection.
- Other names
- AlphaVax filovirus vaccineVRP vaccineRNA particle vaccineVRP-EbolaVRP-Marburg
02
Targets
PYG (Glycogen phosphorylase)Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on Filovirus alphavaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Filovirus alphavaccine.